Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Amlodipine 5 mg Clear all
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

NCT00654745
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Los Angeles, California • Sylmar, California • Tustin, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

NCT03657550
View directory record Official record
Conditions
Hypertension
Interventions
Levamlodipine, Amlodipine, Amlodipine, Levamlodipine
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 30, 2026, 3:02 AM EDT
Recruiting Phase 2 Interventional

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083
View directory record Official record
Conditions
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions
L-NMMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00877929
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 80, Amlodipine 10
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Long Beach, California • Tustin, California • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

NCT04518293
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
Drug
Lead sponsor
George Medicines PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
1,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 30, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

NCT05293756
View directory record Official record
Conditions
Hypertension, Self-Management, Technology, Quality of Life
Interventions
OPTIMA-BP Intervention
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
50 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

NCT00402103
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

NCT00666536
View directory record Official record
Conditions
Hypertension
Interventions
valsartan and amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

NCT02834403
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension

NCT00142584
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol (NEB), Metoprolol (MET)
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 30, 2026, 3:02 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation

NCT02353806
View directory record Official record
Conditions
Chronic Hypertension in Pregnancy
Interventions
Amlodipine besylate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 30, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 30, 2026, 3:02 AM EDT